ResMed Completes Acquisition of Noctrix Health for $340 Million

ResMed completed its acquisition of Noctrix Health, a medical device company developing wearable therapeutics for chronic neurological disorders. The deal expands ResMed’s clinical sleep health portfolio with Noctrix’s Nidra Tonic Motor Activation (TOMAC) therapy for moderate-to-severe Restless Legs Syndrome (RLS), with Noctrix becoming a wholly owned subsidiary. The acquisition was previously announced as a definitive merger agreement to acquire Noctrix for $340 million, expected to close on or around June 1, 2026.